Maravai Q1 revenue $79M, down 68% YoY; net loss $1.3M vs prior net income $146.9M

MARAVAI LIFESCIENCES HOLDINGS, INC.

2023-Q1 EPS reported $0.00 revenue$79,025,000

Revenue $79.0M, -67.7% YoY; net loss $(1.3)M vs net income $146.9M in Q1 2022.
Nucleic Acid Production revenue $61.5M (-72.5% YoY) includes ~$15.9M COVID-19 CleanCap revenue, $157M less YoY.
Biologics Safety Testing revenue $17.6M (-14.9% YoY) driven by post-COVID inventory normalization and China slowdown.
Adjusted EBITDA $23.8M (30.1% margin), down from $187.0M in prior year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MARAVAI LIFESCIENCES HOLDINGS, INC. reported the first quarter ended March 31, 2023 results: revenue $79.0 million, net income $(1.3) million.

Period: the first quarter ended March 31, 2023
Revenue: $79.0 million
Net income: $(1.3) million
Result: reported results

Exact text from the filing

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2023, together with other business updates. Recent highlights include: • Quarterly revenue of $79.0 million, Net loss of $(1.3) million, and Adjusted EBITDA margins of 30.1%;

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

MARAVAI LIFESCIENCES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001823239-23-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.